Novavax, Inc.
NVAX
Positions held
Your positionsNVAX isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-08.
- Novavax is positioned to capitalize on the growing demand for innovative vaccines in the biotechnology sector, particularly as global health challenges continue to evolve.
- In 2025, Novavax reported a revenue of $1.12 billion, with a significant operating margin of 49.0%.
- The company's stock has a target mean price of $14.00, indicating potential upside from current levels.
- Novavax faces intense competition in the biotechnology space, which may impact its market share and pricing power.
- In the most recent quarter, revenue declined by 59% compared to the prior quarter, falling from $140 million to $57 million.
- The company reported an operating margin of -96.8% in Q2 2026, reflecting ongoing financial challenges.
Fundamentals
| Market cap | $1.82B | Enterprise value | $1.39B | Trailing P/E | — | Forward P/E | -17.93 |
| PEG | 1.32 | Price / book | -9.52 | Beta | 2.44 | Dividend yield | 0.00% |
| Revenue growth | -76.3% | Earnings growth | — | Gross margin | -2.6% | Operating margin | -89.6% |
| Profit margin | -59.9% | ROE | — | ROA | -6.5% | Debt / equity | — |
| Current ratio | 2.33 | Free cash flow | $153.39M | Analyst recommendation | buy | Mean target | $14.00 |
| 52w high | $13.39 | 52w low | $6.20 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $56.7M | $140M | $147M | $70.4M | $239M | — |
| Op margin | -96.8% | -11.1% | 10.2% | -115.0% | 42.2% | — |
| Net income | -$53.4M | -$9.5M | $17.5M | -$202M | $107M | — |
| Gross margin | 74.9% | 78.0% | 85.0% | 69.5% | 93.6% | — |
| Gross profit | $42.5M | $109M | $125M | $48.9M | $224M | — |
| Operating income | -$54.9M | -$15.4M | $15.0M | -$81.0M | $101M | — |
- Revenue -59% vs prior quarter ($57M vs $140M).
- Gross margin 74.9% (was 78% prior quarter).
- Operating margin compressed to -96.8%.
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $1.1B | $682M | $556M | $1.6B | — |
| Op margin | 49.0% | -36.5% | -101.8% | -40.3% | — |
| Net income | $440M | -$187M | -$545M | -$658M | — |
| Gross margin | 93.5% | 70.3% | 38.2% | 43.5% | — |
| Gross profit | $1.1B | $479M | $213M | $696M | — |
| Operating income | $551M | -$249M | -$567M | -$645M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Novavax (NVAX) Stock Could Be Above Fair Value As Plague Fears Fade
2026-10-08 · Should Novavax’s Headline-Driven Volatility Around Russia Health Scare Require Action From NVAX Investors?
2026-10-07 · Novavax and Moderna Shares Fall as Citi Assesses Vaccine Sector Volatility
2026-10-06 · Pandemic Panic Is Back on Wall Street. What to Know About the Russian Plague Scare.
2026-10-06 · Novavax, Moderna stocks fall after WHO calls plague risk 'low'
2026-10-06 · Novavax (NVAX) Stock Sinks As Market Gains: Here's Why
2026-10-06 · Novavax Sinks 12% as WHO Calls Plague Risk “Very Low”
2026-10-06 · Novavax Pulls Back From Plague-Scare Spike as Officials Call Risk Low; Moderna and Pfizer Inch Higher
2026-10-06 · Novavax (NVAX) Surges 20.1%: Is This an Indication of Further Gains?
2026-10-06 · NVAX, EBS, ARCT, MRNA Rally After Russia Plague Lab Worker's Death: Retail Traders Eye 'Contract Awards'
2026-10-05 · NVAX Stock Outruns Moderna As Vaxcyte’s Shot Clears A Late-Stage Test
2026-10-02 · 3 Overrated Stocks We Approach with Caution
Price (daily)
Full chart · RSI · MACD · patterns